Few Embryos and Extra Testing: What to Ask Before You Add More

When a cycle produces only a few embryos, the question is rarely “is more testing better?” It is closer to: would this particular test, on this particular embryo, change what we do next — and what might we lose by doing it? Extra testing can mean a repeat biopsy, re-analysis of stored material, or an additional screening step layered onto the PGT you already planned. Each has its own trade-offs, and none of them is automatically the right choice just because it exists.

The useful conversation is about incremental value: the difference the result would make compared with what you would decide without it. That is a clinical judgement call, made with your treating team and, where relevant, a genetic counsellor. Your coordinator can help you prepare the questions and keep the answers in one place, but cannot interpret results or advise on testing.

Why low embryo numbers change the arithmetic

PGT-A assesses chromosome number in cells sampled from an embryo, and testing has limitations — it can produce incorrect findings, and a result does not guarantee a successful pregnancy or a healthy child (HFEA: PGT-A). With many embryos, a test that filters some out still leaves options. With two or three, every result carries more weight, and an inconclusive or unexpected finding can narrow your choices rather than clarify them.

There is also a physical consideration. Embryo biopsy can cause damage and prevent further development (HFEA PGT-A FAQ). That risk exists for any biopsy, including one already planned. A second sampling episode on a small cohort is a different proposition from the first, and the balance of possible benefit against handling risk is something only your clinical team can assess for your embryos.

The trade-offs worth naming out loud

• Handling risk versus information gained. Ask what further sampling would involve and whether the embryo would be handled again, thawed, or re-biopsied, and what that means for its availability for transfer.
• Inconclusive results. Some findings do not give a clean answer. A mosaic PGT-A result is inferred from intermediate chromosome copy-number findings in a biopsy sample; technical factors can contribute, and a sampled result does not establish the cell composition of the whole embryo (ASRM: mosaic PGT-A results). With few embryos, an ambiguous result can leave you with less certainty than you hoped for.
• Cost per embryo. Testing is often priced per embryo or per batch. When the denominator is small, the cost per usable answer rises. Ask how the fee is structured and what happens to charges if a sample fails or a result is uninformative; see what is included in a quoted PGT-A price.
• The decision may not move. The most important question is whether any plausible result would change your transfer plan. If you would transfer the embryo regardless, the test may add cost and waiting without adding a decision.
• Timing. Additional analysis can extend the laboratory phase and shift your travel and return-home dates. PGT results timing and travel planning explains how to keep that flexible.

Questions that get you a real answer

Bring these to your consultation, and ask for answers in writing where possible. They are designed to surface reasoning, not to test your clinician.

1. Given our embryo number and history, what specifically would this additional test tell us that we do not already know?
2. If the result came back as X, what would we do differently? If it came back inconclusive, what then?
3. What are the handling risks of further sampling for these particular embryos, and how do you weigh them?
4. How often do you see uninformative or low-information results in cases like ours, and how do you manage them?
5. What is the all-in cost, including any repeat or re-analysis fee, and what is refunded if no result is obtained?
6. Which test are we actually discussing — PGT-A, PGT-M or PGT-SR — and why? These address different questions: PGT-M concerns a known monogenic condition, PGT-SR concerns chromosomal structural rearrangements, and a treating team and genetic counsellor should discuss the relevant history, test design and suitability (HFEA: PGT-M and PGT-SR).
7. If we decide against further testing, what is the plan for transfer and follow-up?

Question 6 matters because the purpose of testing shapes the trade-off. A test aimed at a known inherited condition answers a different question from a general chromosome screen, and the value of either depends on your history rather than on the number of embryos alone.

Where clinical judgement enters

Guidance on PGT-A is explicit that whether to use it should be discussed for the individual situation (HFEA: PGT-A). That is not a dodge; it reflects that the evidence does not give a single answer for every case, and least of all for a small embryo cohort where a single result can dominate the picture.

Expect your clinician to reason aloud about probabilities rather than certainties, to say when the evidence is thin, and to distinguish a sample finding from a confirmed whole-embryo diagnosis. If a recommendation arrives without that reasoning, it is reasonable to ask for it. You are entitled to ask licensed clinicians about diagnosis, options, risks, reports and your individual chances — that is exactly the conversation this decision needs.

Recording and comparing answers

If you are gathering opinions from more than one clinic, keep the comparison structured so that wording differences do not masquerade as substance. A simple table works:

Item to record	Clinic A	Clinic B
Test proposed and its purpose
What result would change the plan
Handling or re-biopsy implications
Fee structure and refund terms
Expected added time before transfer
Who explains results, and when

Note the date of each conversation and who said what. If you are coordinating care across countries, ask which clinician will explain results and by what route, and whether a genetic counselling discussion is included. Our questions to ask before starting PGT in Thailand covers the broader preparation list, and if a cycle has already produced few usable embryos, what to review after repeated culture failure or few usable embryos sets out the review points.

A worked planning example

Suppose a couple has three blastocysts and the clinic proposes an additional screening step before transfer. Before agreeing, they write down three scenarios: a clear result, an inconclusive result, and no further testing. In the first, they would transfer the embryo indicated. In the second, they would want a genetic counselling conversation before deciding. In the third, they would proceed with transfer as planned. Because the third and first scenarios lead to broadly the same action, the couple asks the clinic what the additional step would change — and asks for the answer, and the fee terms, in writing. That is not a refusal to test; it is a request for the reasoning behind it.

If you would like help assembling those questions, organising prior records, or arranging a remote consultation to discuss them, our coordination team can support the preparation and communication. Scope and any fees are confirmed individually, and clinical advice stays with your treating clinicians.

Frequently asked questions

Can I ask my clinician directly about my own chances and results?

Yes. Licensed clinicians can discuss your diagnosis, options, risks, reports and individual chances. A coordination service can help you prepare questions and organise records, but does not interpret results or recommend testing.

Does a normal PGT result mean the embryo will definitely lead to a pregnancy?

No. Testing has limitations and can produce incorrect findings, and a result does not guarantee a successful pregnancy or a healthy child. Your clinician can explain what a result does and does not tell you in your situation.